Spravato vs Ketamine IV: Comparing Esketamine Nasal Spray to IV Infusions

IV ketamine is usually easier to reach than Spravato, because Spravato (esketamine nasal spray) can only be given at a treatment center certified under the FDA’s Risk Evaluation and Mitigation Strategy (REMS), with at least 2 hours of on-site monitoring after every dose, while IV ketamine infusions carry no REMS and are offered off label at many more ketamine clinics. Spravato is FDA approved for treatment-resistant depression and is often covered by insurance with prior authorization, whereas IV ketamine is almost always paid out of pocket.

If you are weighing ketamine-based treatment for depression, one of the first decisions you will face is whether to pursue Spravato (the FDA-approved esketamine nasal spray) or IV ketamine infusions (the off-label but more extensively studied option). They are related but not interchangeable, and the differences go beyond delivery method.

Both options act on the same molecule family and the same receptor, the NMDA glutamate receptor, but they reach patients through different regulatory paths. The sections below cover pharmacology, trial evidence, REMS access, side effects, cost and the practical steps of finding a provider, so you can have an informed conversation with your psychiatrist or prescriber.

Spravato vs IV Ketamine: Side-by-Side Comparison

Spravato and IV ketamine differ on six attributes that shape access: the active ingredient, the route, the FDA status, the dosing, the setting and the payer. The table below sets them out using figures already established by the FDA label and the published trials discussed further down.

The Pharmacology: S-Enantiomer vs. Racemic Mixture

Every ketamine molecule exists in one of two mirror-image forms: S-ketamine (esketamine) and R-ketamine (arketamine). Standard IV ketamine is racemic, meaning it contains a 50/50 mix of both forms. Spravato contains only esketamine.

This matters because the two enantiomers have different pharmacological properties:

• Esketamine (S-ketamine) binds to NMDA receptors with approximately 3 to 4 times greater affinity than R-ketamine. It is more potent as an anesthetic and produces stronger dissociative effects at equivalent doses.
• Arketamine (R-ketamine) has weaker NMDA binding but appears to have its own antidepressant mechanisms. Animal studies published in Pharmacology Biochemistry and Behavior (2017) found that R-ketamine produced longer-lasting antidepressant effects than S-ketamine in rodent models, possibly through different downstream pathways involving AMPA receptors and BDNF signaling.

The implication is that racemic ketamine may offer something that esketamine alone does not: the combined activity of both enantiomers, each contributing different mechanisms of antidepressant action. Some researchers, including Kenji Hashimoto at Chiba University, have argued that R-ketamine may actually be the more important enantiomer for treating depression, with fewer side effects than S-ketamine. This hypothesis is still being tested in human trials (arketamine is currently in Phase II clinical trials).

Dose numbers are not directly comparable between the two products. Esketamine is roughly twice as potent at the NMDA receptor as the racemic mix, and nasal absorption is less complete and less predictable than an infusion, which is one reason IV ketamine gives the clinician tighter control over the dose that reaches the bloodstream.

Efficacy: What the Trials Show

IV Ketamine Evidence

IV racemic ketamine has been studied in dozens of randomized controlled trials since the landmark Zarate study in 2006. Key findings:

• Response rates of 50 to 70% in treatment-resistant depression (TRD), typically within 24 hours of a single infusion.
• The Murrough 2013 trial (the largest at the time) showed a 64% response rate vs. 28% for active placebo (midazolam) at 24 hours.
• Rapid reduction in suicidal ideation, often within hours, as documented in the Wilkinson 2018 meta-analysis.
• Effects of a single infusion typically last 1 to 2 weeks; repeated infusions (6 over 2 to 3 weeks) produce more durable responses.
• Most trials are independently funded by academic institutions or the NIH.

The largest pragmatic trial of IV ketamine to date did not compare it with Spravato. The ELEKT-D trial, published by Amit Anand and colleagues in the New England Journal of Medicine (2023) and funded by the Patient-Centered Outcomes Research Institute (PCORI), randomized 403 patients with nonpsychotic treatment-resistant depression to IV ketamine or electroconvulsive therapy (ECT) and found ketamine noninferior to ECT, with less short-term memory loss.

Spravato Evidence

Spravato’s FDA approval was based on several Phase III trials funded by Janssen (Johnson & Johnson’s pharmaceutical division):

• TRANSFORM-1, TRANSFORM-2, and TRANSFORM-3 were the pivotal trials. Of these, only TRANSFORM-2 met its primary endpoint, showing a statistically significant improvement in depression scores (MADRS) compared to placebo nasal spray plus a new oral antidepressant. TRANSFORM-1 and TRANSFORM-3 did not reach statistical significance on their primary endpoints.
• The SUSTAIN-1 long-term maintenance trial showed that patients who continued Spravato had lower relapse rates than those switched to placebo.
• Spravato also received FDA approval in 2020 for major depressive disorder with acute suicidal ideation or behavior, based on the ASPIRE I and ASPIRE II trials, which showed rapid (within 24 hours) reduction in depressive symptoms compared to placebo.

The mixed results of the pivotal trials have been a source of debate. Critics point out that two of three Phase III trials failed their primary endpoint, and that the magnitude of benefit in TRANSFORM-2 was modest compared to what is typically reported in IV ketamine trials. Supporters counter that the trial design (adding Spravato vs. placebo on top of a new oral antidepressant) made it harder to show separation, since both groups were starting a new medication.

In January 2025 the FDA expanded the Spravato label to allow use as monotherapy for adults with treatment-resistant depression, so a new oral antidepressant is no longer required alongside it. The REMS conditions described below apply to monotherapy in the same way.

Head-to-Head Comparisons

Direct randomized comparisons between IV racemic ketamine and intranasal esketamine remain scarce, so most of the comparison rests on indirect evidence. The strongest synthesis is a meta-analysis by Anees Bahji, Gustavo Vazquez and Carlos Zarate in the Journal of Affective Disorders (2021), which pooled 24 trials with 1,877 participants and found that racemic ketamine showed greater overall response and remission rates than esketamine, along with lower dropout. The authors concluded that IV ketamine appears more efficacious than intranasal esketamine for depression.

That conclusion carries real limits. The trials differed in design, dose and patient population, few compared the two drugs in the same study, and indirect comparisons can overstate a gap. Treat the evidence as pointing toward IV ketamine on efficacy, not as settling the question for any one patient.

The REMS Program: What It Means in Practice

Because of concerns about misuse, sedation, and dissociation, the FDA requires Spravato to be distributed under a Risk Evaluation and Mitigation Strategy (REMS). In practical terms, this means:

• Spravato can only be administered at a certified healthcare facility enrolled in the REMS program.
• Patients self-administer the nasal spray under the direct supervision of a healthcare provider.
• You must be monitored in the clinic for at least 2 hours after each dose.
• You cannot take Spravato home, and you cannot drive or operate machinery until the next day.
• The prescribing provider, the pharmacy, and the healthcare facility all must be enrolled in the REMS.

IV ketamine has no REMS requirement. However, responsible clinics provide similar levels of monitoring (vital signs, supervised recovery period, no driving on treatment day).

What does REMS certification require of a treatment center?

A Spravato REMS-certified treatment center must enroll in the program, train its staff, keep the drug on site, and report monitoring data to the REMS for each patient session. The FDA added a respiratory depression warning in 2023, and its 2025 approval letter for that REMS modification requires certified settings to have a pulse oximeter to monitor patients on site.

Patients must also be enrolled in the REMS before their first dose. Blood pressure is checked before the spray and again during the observation window, because esketamine can raise blood pressure for a few hours after dosing.

Why does REMS limit where Spravato is available?

REMS certification limits access because every site needs a treatment room, trained staff and a 2-hour observation slot per patient, plus enrollment paperwork and payer prior authorization. Many psychiatry practices can prescribe Spravato but cannot host sessions, so patients are referred to a smaller set of certified centers, often in larger metro areas.

IV ketamine clinics face no REMS, so they open wherever a licensed prescriber and monitoring staff are available. That is the main reason IV ketamine is easier to find outside major cities, even though patients usually pay for it themselves.

How to Find a REMS-Certified Spravato Center or an IV Ketamine Clinic

Finding care follows a different path for each option. Spravato access runs through your prescriber, your insurer and the REMS center list, while IV ketamine access runs through clinic screening and your budget.

1. Confirm the diagnosis and treatment history. Both options are aimed at treatment-resistant depression, which payers usually define as an inadequate response to at least 2 antidepressants at an adequate dose and duration.
2. Ask your psychiatrist which route fits. A psychiatrist or psychiatric nurse practitioner can prescribe Spravato and refer you to a certified center, or refer you for ketamine infusions.
3. For Spravato, check insurance first. Ask your plan whether prior authorization is approved and which REMS-certified centers are in network, then confirm the center can schedule twice-weekly sessions for the first 4 weeks.
4. For IV ketamine, compare clinics on screening and staffing. Ask who places the IV, who monitors you, how dosing is set, whether the clinic coordinates with your therapist or psychiatrist, and what the total cost of an initial series is.
5. Plan transport for every session. Neither option allows you to drive yourself home on treatment day.

The regenerated.com directory lists ketamine therapy clinics across the United States, and you can narrow the list by state or city, then read each clinic profile to see whether it lists IV infusions, Spravato sessions or both. Listing order is not paid ranking, Featured slots are labeled and capped, and Verified means a clinic completed credential checks, not that it spent money; the directory is free for patients, and inclusion is not an endorsement. The guide to Featured, Verified and organic listings explains each label.

Who Prescribes and Administers Each Treatment?

Spravato is usually prescribed by a psychiatrist or psychiatric nurse practitioner and given in a psychiatry practice, hospital outpatient department or dedicated treatment center that holds REMS certification. A nurse or other trained clinician observes each session and records vital signs and dissociation for the REMS.

IV ketamine clinics are often led by anesthesiologists, emergency physicians, psychiatrists or nurse anesthetists (CRNAs), depending on state rules. Some clinics are psychiatry-led and pair infusions with ketamine-assisted psychotherapy; others are infusion-only and expect your own psychiatrist to manage your antidepressants and follow-up.

Side Effects Comparison

Side Effect	IV Ketamine (Racemic)	Spravato (Esketamine)
Dissociation	Common; typically mild to moderate	Common; may be more intense per mg due to higher NMDA affinity
Nausea	10 to 20%	20 to 30%
Elevated blood pressure	Transient; monitored during infusion	Transient; monitored per REMS
Headache	Common	Common
Dizziness/sedation	Common	Common
Nasal discomfort	N/A	Common (taste, irritation)
Duration of monitoring	30 to 60 min post-infusion (clinic-dependent)	2 hours minimum (REMS requirement)

Some patients tolerate one form better than the other. Patients who are needle-averse may prefer the nasal spray. Patients who experience significant nasal discomfort or who have sinus issues may prefer IV administration.

Spravato carries an FDA boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in younger patients. Racemic ketamine shares the same class risks, and long-term frequent use of ketamine has been linked to bladder problems (ketamine cystitis), which is one reason clinics space out maintenance sessions.

Who should not use Spravato or IV ketamine?

The Spravato label lists three contraindications: aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial and peripheral arteries) or arteriovenous malformation, a history of intracerebral hemorrhage, and hypersensitivity to esketamine or ketamine. IV ketamine clinics screen for similar issues, along with uncontrolled high blood pressure, a history of psychosis, active substance use disorder and pregnancy.

Insurance Coverage and Cost

This is often the deciding factor for patients. The cost structures are very different:

Spravato

• List price: $590 to $885 per session (depending on dose: 56 mg or 84 mg)
• Insurance: Many commercial plans and Medicare Part D cover Spravato with prior authorization. Prior auth typically requires documented failure of at least 2 antidepressants.
• Patient copay: Varies widely, from $0 to $250+ per session depending on your plan. Janssen offers a savings program (CarePath) that can reduce costs for commercially insured patients.
• First-year cost with insurance: $1,000 to $5,000+ (estimated, highly variable by plan)

IV Ketamine

• Per session: $400 to $800
• Initial series (6 infusions): $2,400 to $4,800
• Monthly maintenance: $400 to $800 per infusion
• Insurance: Rarely covered; off-label use. Some patients have success with HSA/FSA funds.
• First-year cost: $4,000 to $10,000+

Spravato bills differ from IV ketamine bills in structure as well as size. A Spravato session usually produces two charges, the drug itself (through pharmacy or medical benefits) and the facility and observation time, while an IV ketamine clinic quotes one bundled cash price. The full breakdown of ketamine therapy costs and the guide to insurance coverage for ketamine cover appeals, superbills and HSA use in more detail.

Convenience and Practical Considerations

Factor	IV Ketamine	Spravato
Session length (including monitoring)	60 to 90 minutes total	2.5 to 3 hours (administration + REMS monitoring)
Frequency (initial phase)	3x/week for 2 weeks (typical)	2x/week for 4 weeks
Frequency (maintenance)	Monthly or as needed	Weekly to biweekly, then as needed
Clinic availability	Hundreds of ketamine clinics nationwide	Fewer REMS-certified locations, but growing
Need for driver	Yes	Yes

The time commitment is the hidden cost of Spravato. Eight sessions of 2.5 to 3 hours in the first month, each needing a ride home, is a real burden for people who work or care for others, and it matters more when the nearest certified center is far away. IV ketamine compresses the induction phase into about 2 weeks with shorter visits.

Which One Is Right for You?

There is no single right answer. Here are some scenarios to consider:

• Insurance covers Spravato and cost is your top concern: Start with Spravato. The financial burden will likely be lower, and if it works, you have a sustainable long-term option.
• You are paying out of pocket: IV ketamine is often the better value per session, has a larger independent evidence base, and gives your clinician more flexibility with dosing.
• You tried Spravato without adequate response: IV racemic ketamine is worth trying. The R-enantiomer component may produce a different or better response for some individuals.
• You are needle-averse: Spravato avoids the IV line entirely, which matters for comfort and compliance.
• You have severe or acute suicidal ideation: Both have evidence, but IV ketamine offers the most rapid onset and the most precise dose control in urgent situations. Discuss with your psychiatrist.
• There is no REMS-certified center within reach: IV ketamine is often the more practical route, since infusion clinics do not need REMS enrollment and operate in more locations.

Whatever you choose, work with a provider experienced in ketamine-based treatments who can monitor your response and adjust the approach as needed. For more on ketamine’s role in depression treatment, see our full guide on ketamine for depression.

If neither ketamine option suits you, transcranial magnetic stimulation is another FDA-cleared treatment for depression that has not responded to medication; the comparison of TMS and ketamine covers that choice. The ketamine therapy treatment guide explains how sessions work, and the TMS treatment guide describes how magnetic stimulation is delivered over several weeks of daily sessions.

The Bottom Line

Spravato and IV ketamine are both legitimate treatments for treatment-resistant depression, and both work through NMDA receptor blockade. The choice between them often comes down to insurance coverage, cost tolerance, convenience, and individual response. Spravato has the regulatory advantage and insurance access. IV ketamine has the deeper research base and the potential advantage of racemic pharmacology. Some patients end up trying both before finding what works best for them.

On access, the deciding factor is the REMS. Spravato is limited to certified treatment centers with a 2-hour observation window, while IV ketamine is available at a wider range of infusion clinics without REMS enrollment, usually at cash prices.

Neither is a magic bullet. Both work best as part of a broader treatment plan that includes therapy, lifestyle modification, and ongoing psychiatric care.

Related Reading

• Ketamine Therapy: The Complete Guide
• Ketamine for Depression: Evidence, Protocols, and What to Expect
• Ketamine Therapy Cost Breakdown
• Is Ketamine Therapy Covered by Insurance?
• Ketamine Nasal Spray: How Esketamine Is Used
• Ketamine Infusion Therapy: What a Session Involves

Frequently Asked Questions

What is the difference between Spravato and IV ketamine?

Spravato is an FDA-approved nasal spray that contains only esketamine, the S-enantiomer of ketamine, while IV ketamine infusions use racemic ketamine, a 50/50 mix of S- and R-ketamine. Spravato is self-administered under supervision at a REMS-certified center with at least 2 hours of monitoring. IV ketamine is infused by clinic staff, has no REMS, and is used off label for depression, so it is usually paid in cash.

Is Spravato FDA approved and is IV ketamine legal?

Spravato is FDA approved for treatment-resistant depression (2019), for major depressive disorder with acute suicidal ideation or behavior (2020), and since January 2025 as monotherapy for treatment-resistant depression. IV ketamine is legal: it is an FDA-approved anesthetic and a Schedule III controlled substance, and licensed physicians may prescribe it off label for depression, but it is not FDA approved for that specific use.

How much do Spravato and IV ketamine cost, and does insurance cover them?

Spravato has a list price of $590 to $885 per session, and many commercial plans and Medicare Part D cover it with prior authorization, putting first-year cost with insurance at roughly $1,000 to $5,000 or more. IV ketamine runs $400 to $800 per session, or $2,400 to $4,800 for an initial series of six infusions, with a first-year cost of $4,000 to $10,000 or more. IV ketamine is rarely covered because its use for depression is off label.

How well do they work for depression?

IV ketamine shows response rates of 50 to 70% in treatment-resistant depression, and Murrough (2013) reported a 64% response at 24 hours versus 28% for midazolam. For Spravato, only TRANSFORM-2 of three Phase III trials met its primary endpoint. A 2021 meta-analysis by Bahji, Vazquez and Zarate found higher response and remission with IV racemic ketamine than with esketamine, though few trials compared the two directly.

What are the side effects and how long is monitoring?

Both can cause dissociation, nausea, raised blood pressure, headache, and dizziness or sedation. Nausea occurs in about 10 to 20% of IV ketamine sessions versus 20 to 30% for Spravato, which can also cause nasal discomfort and a bitter taste. Spravato requires at least 2 hours of on-site monitoring under its REMS, while IV ketamine clinics typically monitor for 30 to 60 minutes after the infusion ends.

What does a typical treatment schedule look like?

IV ketamine typically starts at 3 infusions per week for 2 weeks, about 6 in total, then moves to monthly or as-needed maintenance. Spravato typically starts at 2 sessions per week for 4 weeks, then moves to weekly or every-other-week dosing and later as-needed sessions. Neither is a magic bullet, and both work best inside a broader plan that includes therapy and ongoing psychiatric care.